Orange Avenue Technologies LLC enter into a Stock Purchase Agreement to acquire Motif BioSciences, Inc. from Motif Bio plc (AIM:MTFB)on February 26, 2021.As consideration for the Transaction, Motif will receive the nominal amount of $1 in addition to an interest in revenue that is derived from Motif Inc’s iclaprim asset. Pursuant to the terms of the SPA, if Motif Inc generates revenue from the iclaprim asset above its outstanding liabilities, Motif Inc shall retain the first $250,000 in revenue and thereafter, 90 per cent of any additional revenue will be paid to the Company, and the remaining 10 per cent of any additional revenue will be retained by Motif Inc. David Hignell, Caroline Rowe,Vadim Alexandre and Rob Rees of SP Angel Corporate Finance LLP acted as financial advisor in transaction.